SCHEMBL7549487

SCHEMBL7549487

N=C(N)NCCC[C@H](NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)NC(=O)c1ccc2ccccc2c1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPY4R P50391 11/20 0.46
NPY1R P25929 6/20 0.46
NPY2R P49146 4/20 0.46
NPY5R Q15761 4/20 0.46
MCHR1 Q99705 1/20 0.43
HDAC1 Q13547 5/20 0.42
HDAC3 O15379 4/20 0.42
HDAC4 P56524 4/20 0.42
HDAC7 Q8WUI4 4/20 0.42
HDAC2 Q92769 4/20 0.42
HDAC10 Q969S8 4/20 0.42
HDAC11 Q96DB2 4/20 0.42
HDAC8 Q9BY41 4/20 0.42
HDAC6 Q9UBN7 4/20 0.42
HDAC9 Q9UKV0 4/20 0.42
HDAC5 Q9UQL6 4/20 0.42
METAP2 P50579 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8416482 0.92 HDAC1 (0.47) HDAC1HDAC3HDAC4HDAC7HDAC2
SCHEMBL537084 0.92 NPY4R (0.45) NPY4RNPY1RNPY2RNPY5RMCHR1
SCHEMBL8512961 0.91 MCHR1 (0.42) NPY4RNPY1RNPY2RNPY5RMCHR1
Hydrochloric Acid SCHEMBL7850288 0.91 NPY4R (0.44) NPY4RNPY1RNPY2RNPY5RMCHR1
Bromide SCHEMBL11101365 0.91 HDAC1 (0.46) HDAC1HDAC3HDAC4HDAC7HDAC2
SCHEMBL8515668 0.89 HDAC1 (0.45) NPY4RNPY1RNPY2RNPY5RMCHR1
SCHEMBL8882210 0.86 ITGB3 (0.44) NPY4RNPY1RNPY2RNPY5RMCHR1
SCHEMBL27352129 0.84 NPY4R (0.47) NPY4RNPY1RNPY2RNPY5R
SCHEMBL8341764 0.84 NPY4R (0.47) NPY4RNPY1RNPY2RNPY5R
SCHEMBL10434863 0.83 NPY4R (0.43) NPY4RNPY1RNPY2RNPY5R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11726094-B2 Methods for determining DPP3 and therapeutic methods 4TEEN4 Pharmaceuticals GmbH (DE) 2023-08-15 US disclosed
EP-3896450-A1 METHODS FOR DETERMINING DPP3 AND THERAPEUTIC METHODS 4TEEN4 Pharmaceuticals GmbH (DE) 2021-10-20 EP disclosed
EP-3854817-A1 METHODS FOR DETERMINING DPP3 AND THERAPEUTIC METHODS 4TEEN4 Pharmaceuticals GmbH (DE) 2021-07-28 EP disclosed
US-20200378977-A1 METHODS FOR DETERMINING DPP3 AND THERAPEUTIC METHODS 4TEEN4 Pharmaceuticals GmbH (DE) 2020-12-03 US disclosed
US-20190145981-A1 METHODS FOR DETERMINING DPP3 AND THERAPEUTIC METHODS SPHINGOTEC THERAPEUTICS GMBH (DE) 2019-05-16 US disclosed
EP-0659886-B1 Enzymatic conversion of proteins using immobilized dictyostelium dipeptidylaminopeptidase LILLY CO ELI (US) 2002-07-03 EP disclosed
EP-0595476-B1 Dictyostelium dipeptidylaminopeptidase LILLY CO ELI (US) 2001-12-19 EP disclosed
EP-1094118-A1 Enzymatic conversion of precursor proteins using a dictyostelium dipeptidylaminopeptidase ELI LILLY AND COMPANY (US) 2001-04-25 EP disclosed
US-6027911-A REMOVING AMINO-TERMINAL DIPEPTIDES FROM PRECURSOR POLYPEPTIDE BY IMMOBILIZING CATHEPSIN C ONTO SUPPORT SURFACE, THEN INCUBATING WITH POLYPEPTIDE AND RECOVERING PROCESSED POLYPEPTIDE ELI LILLY AND COMPANY (US) 2000-02-22 US disclosed
US-6008041-A NUCLEOTIDE SEQUENCE WHICH ENCODES SINGLE POLYPEPTIDE WHICH CAN BE PROCESSED INTO MATURE PROTEIN; FOR GENETICALLY ENGINEERED PRODUCTION OF ENZYME ELI LILLY AND COMPANY (US) 1999-12-28 US disclosed
EP-0898615-A1 BOVINE DIPEPTIDYLAMINOPEPTIDASE 1 ELI LILLY AND COMPANY (US) 1999-03-03 EP disclosed
WO-1997042306-A1 BOVINE DIPEPTIDYLAMINOPEPTIDASE 1 ELI LILLY AND COMPANY (US) 1997-11-13 WO disclosed
US-5565330-A Method for removing N-terminal dipeptides from precursor polypeptides with dipeptidylaminopeptidase from Dictyostelium discoideum ELI LILLY AND COMPANY (US) 1996-10-15 US disclosed
US-5565349-A ISOLATED FROM SLIME MOLDS; USEFUL IN REMOVING DIPEPTIDES FROM N-TERMINUS OF GENETICALLY ENGINEERED PEPTIDES ELI LILLY AND COMPANY (US) 1996-10-15 US disclosed
EP-0659886-A1 Enzymatic conversion of proteins using immobilized dictyostelium dipeptidylaminopeptidase ELI LILLY AND COMPANY (US) 1995-06-28 EP disclosed
EP-0595476-A2 Dictyostelium dipeptidylaminopeptidase ELI LILLY AND COMPANY (US) 1994-05-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190145981-A1 METHODS FOR DETERMINING DPP3 AND THERAPEUTIC METHODS DPP3, DPP4, DPP7 NPY4R 852/4885NPY1R 1684/4885NPY2R 1563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.